ATRS - Antares Pharma, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.4450
+0.1450 (+3.37%)
As of 12:29PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close4.3000
Open4.3600
Bid4.4400 x 2200
Ask4.4500 x 3100
Day's Range4.3000 - 4.5350
52 Week Range2.5300 - 4.5350
Volume2,053,997
Avg. Volume1,274,141
Market Cap725.54M
Beta (3Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.0040
Earnings DateNov 5, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.44
  • GlobeNewswire

    REMINDER: Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma Enters Into a Global Development Agreement With Idorsia Pharmaceuticals Ltd.

    Selatogrel, a new chemical entity (NCE), is being developed for the treatment of a suspected acute myocardial infarction (AMI) in adult patients with a history of AMI. Idorsia’s Phase 2 clinical data demonstrated that subcutaneous administration of selatogrel resulted in a potent and rapid platelet inhibition effect in patients with a history of coronary artery disease and AMI.

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 London Healthcare Conference on Wednesday November 20, 2019, at 11:20 am (GMT) / 6:20 am (EST) in London, UK. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 5-Nov-19 1:30pm GMT

    Q3 2019 Antares Pharma Inc Earnings Call

  • GlobeNewswire

    Antares Pharma Reports Third Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $34.3 Million – Earnings Per Share of $0.01 The Company Increases Full Year 2019 Revenue Guidance to a Range of $115.0 to $120.0 Million EWING,.

  • Hedge Funds Are Selling Antares Pharma Inc (ATRS)
    Insider Monkey

    Hedge Funds Are Selling Antares Pharma Inc (ATRS)

    It is already common knowledge that individual investors do not usually have the necessary resources and abilities to properly research an investment opportunity. As a result, most investors pick their illusory “winners” by making a superficial analysis and research that leads to poor performance on aggregate. Since stock returns aren't usually symmetrically distributed and index […]

  • GlobeNewswire

    Antares Pharma Announces Receipt of Final Payment From Sale of Zomajet™ Needle-Free Delivery System

    Antares Pharma, Inc. (ATRS) (“Antares” or “Company”) today announced that it has received the final payment of $2.5 million from Ferring Pharmaceuticals (“Ferring”) in connection with the previously disclosed sale of Antares’ worldwide rights, including certain fixed assets, for the ZOMAJET™ needle-free auto injector device to Ferring. Antares had been the worldwide supplier of ZOMAJET™ devices to Ferring and JCR Pharmaceutical Company Ltd. “This strategic divestiture has allowed us to continue to focus on developing combination products using our auto injector and pen platforms for ourselves and our partners,” stated Robert F. Apple, President and Chief Executive Officer of the Company.

  • GlobeNewswire

    Antares Pharma to Report Third Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its third quarter 2019 financial results and recent operating progress before the market opens on Tuesday, November 5, 2019.  Management will host a webcast and conference call at 8:30 a.m. ET (Eastern Time) on November 5, 2019 to discuss the results.

  • GlobeNewswire

    Antares Pharma Announces Two Poster Presentations at the 2019 Sexual Medicine Society Scientific Annual Meeting

    The poster entitled “Comparison of Pharmacokinetic Profiles of Testosterone Therapy Products in Relation to Diurnal Variation of Serum Testosterone Levels” will be presented by Alexander Pastuszak, MD, PhD, University of Utah School of Medicine, Salt Lake City, Utah. The goal of the study was to review the pharmacokinetic (PK) profiles of serum testosterone in different exogenous testosterone formulations and compare these PK profiles with daily variations in endogenous serum testosterone levels. A review of daily testosterone variation studies in adult men was conducted followed by literature searches and product prescribing information review of a variety of testosterone therapies.

  • Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?
    Simply Wall St.

    Do Directors Own Antares Pharma, Inc. (NASDAQ:ATRS) Shares?

    The big shareholder groups in Antares Pharma, Inc. (NASDAQ:ATRS) have power over the company. Large companies usually...

  • GlobeNewswire

    Antares Pharma to Present at the Ladenburg Thalmann 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24, 2019 at 12:00 p.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).

  • Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?
    Simply Wall St.

    Does Antares Pharma (NASDAQ:ATRS) Have A Healthy Balance Sheet?

    David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 6-Aug-19 12:30pm GMT

    Q2 2019 Antares Pharma Inc Earnings Call

  • Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript
    Motley Fool

    Antares Pharma Inc (ATRS) Q2 2019 Earnings Call Transcript

    ATRS earnings call for the period ending June 30, 2019.

  • Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven
    Simply Wall St.

    Loss-Making Antares Pharma, Inc. (NASDAQ:ATRS) Expected To Breakeven

    Antares Pharma, Inc.'s (NASDAQ:ATRS): Antares Pharma, Inc. focuses on developing and commercializing self-administered...

  • GlobeNewswire

    Antares Pharma Reports Second Quarter 2019 Operating and Financial Results

    Record Quarterly Revenue of $28.4 Million - Double Second Quarter 2018 Revenue The Company Increases Full Year 2019 Revenue Guidance to a Range of $100.0 to $110.0 Million.

  • GlobeNewswire

    Antares Pharma to Report Second Quarter 2019 Financial and Operating Results

    Antares Pharma, Inc. (ATRS) today announced it will release its second quarter 2019 financial results and recent operating progress before the market opens on Tuesday, August 6, 2019. Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma Announces Amendment to Existing Loan and Security Agreement With Hercules Capital

    Antares Pharma, Inc. (ATRS) (“Antares” or “the Company”) today announced that it has entered into an amendment to its existing loan and security agreement with Hercules Capital, Inc. (HTGC), (“Hercules”), to increase the available debt capital by $25 million for a term loan of up to $50 million. At the same time Antares also provided notice of the termination of the At-The-Market (“ATM”) equity offering facility which will be effective on July 6, 2019.

  • Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)
    Insider Monkey

    Here is What Hedge Funds Think About Antares Pharma Inc (ATRS)

    We at Insider Monkey have gone over 738 13F filings that hedge funds and famous value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st. In this article we look at what those investors think of Antares Pharma Inc (NASDAQ:ATRS). Is Antares […]

  • GlobeNewswire

    Antares Pharma to Present at the Raymond James 2019 Life Sciences and MedTech Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Raymond James 2019 Life Sciences and MedTech Conference on Tuesday, June 18, 2019 at 10:20 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?
    Simply Wall St.

    Have Insiders Been Selling Antares Pharma, Inc. (NASDAQ:ATRS) Shares This Year?

    We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...

  • GlobeNewswire

    Antares Pharma to Present at the Jefferies 2019 Healthcare Conference

    Antares Pharma, Inc. (ATRS) today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2019 Healthcare Conference on Thursday, June 6, 2019 at 11:00 a.m. Eastern Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • GlobeNewswire

    Antares Pharma to Present at the B. Riley FBR Institutional Investor Conference

    Antares Pharma, Inc. (ATRS) today announced that Fred M. Powell, Executive Vice President and Chief Financial Officer, will present at the B. Riley FBR Institutional Investor Conference on Thursday May 23, 2019 at 1:30 pm Pacific Daylight Time. Antares Pharma, Inc. is a combination drug device company focused on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology.  The Company has a portfolio of proprietary and partnered commercial products with several product candidates in advanced stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. and Pfizer Inc. (Pfizer).  Antares Pharma’s proprietary products include XYOSTED™ (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

  • Thomson Reuters StreetEvents

    Edited Transcript of ATRS earnings conference call or presentation 2-May-19 12:30pm GMT

    Q1 2019 Antares Pharma Inc Earnings Call